COVIVAC, Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein ± adjuvant CpG 1018, developed by Institute of Vaccines and Medical Biologicals, Vietnam is in phase1/2 and NDV-HXP-S; A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine, developed by Sean Liu, Icahn School of Medicine at Mount Sinai is in phase 1 [7]. The gene discussed is PROS1; the disease is COVID-19.